Kevin Dieckhaus

Dr. Kevin Dieckhaus

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
KDKevin Dieckhaus
Kevin Dieckhaus
PKPeterson S Kyebambe
Peterson S Kyebambe
Background: Brucellosis is a zoonotic infection transmitted to humans through direct contact with infected animals, their products, or excreta such as urine or dung. Brucellosis is associated with significant morbidity in Southwestern Uganda, where cattle and goat rearing are a major economic industry. As in many settings in sub-Saharan Africa, diagnosis and management of brucellosis remain a challenge due to the presence of comorbidities and limitations in resources for diagnostic testing and therapy. Methods: A chart review was conducted to characterize the clinical manifestations, diagnosis, comorbidities, and management of 101 patients treated for brucellosis at the Kabale Regional Referral Hospital from September 2002 to May 2010. Results: Patients presented with substantial comorbidities. The most common manifestation of illness was osteoarticular, but disease manifestations were quite varied. A high rate of focal illness in this cohort (77%) was observed. Conclusions: Clinicians in this setting should be cognizant of the varied presentations, comorbidities, and treatment options for this disease.

4 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
KDKevin Dieckhaus
Kevin Dieckhaus
MKMinjung Kim
Minjung Kim
JSJian-Bing Shen
Jian-Bing Shen
TLTina S. Liang
Tina S. Liang
MKMichael J. Kleinberg
Michael J. Kleinberg
BLBruce T. Liang
Bruce T. Liang
Since the emergence of SARS-CoV-2, maintaining healthcare worker (HCW) health and safety has been fundamental to responding to the global pandemic. Vaccination with mRNA-base vaccines targeting SARS-CoV-2 spike protein has emerged as a key strategy in reducing HCW susceptibility to SARS-CoV-2, however, neutralizing antibody responses subside with time and may be influenced by many variables. We sought to understand the dynamics between vaccine products, prior clinical illness from SARS-CoV-2, and incidence of vaccine-associated adverse reactions on antibody decay over time in HCWs at a university medical center. A cohort of 296 HCWs received standard two-dose vaccination with either bnt162b2 (Pfizer/BioNTech) or mRNA-1273 (Moderna) and were evaluated after two, six, and nine months. Subjects were grouped by antibody decay curve into steep antibody decliners gentle decliners. Vaccination with mRNA-1273 led to more sustained antibody responses compared to bnt162b2. Subjects experiencing vaccine-associated symptoms were more likely to experience a more prolonged neutralizing antibody response. Subjects with clinical SARS-CoV-2 infection prior to vaccination were more likely to experience vaccination-associated symptoms after first vaccination and were more likely to have a more blunted antibody decay. Understanding factors associated with vaccine efficacy may assist clinicians in determining appropriate vaccine strategies in HCWs.

1 January 2020 in Journal of the International Association of Providers of AIDS Care (JIAPAC)
Verified
Journal Article
Open access
PDF file
KDKevin Dieckhaus
Kevin Dieckhaus
Toan HaToan Ha
Toan Ha
SSStephen L. Schensul
Stephen L. Schensul
ASAvina Sarna
Avina Sarna
Background: The rollout of antiviral therapy in Low and Middle Income Countries (LMICs) has reduced HIV transmission rates at the potential risk of resistant HIV transmission. We sought to predict the risk of wild type and antiviral resistance transmissions in these settings. Methods: A predictive model utilizing viral load, ART adherence, genital ulcer disease, condom use, and sexual event histories was developed to predict risks of HIV transmission to wives of 233 HIV+ men in 4 antiretroviral treatment centers in Maharashtra, India. Results: ARV Therapy predicted a 5.71-fold reduction in transmissions compared to a model of using condoms alone, with 79.9%, of remaining transmissions resulting in primary ART-resistance. Conclusions: ART programs reduce transmission of HIV to susceptible partners at a substantial increased risk for transmission of resistant virus. Enhanced vigilance in monitoring adherence, use of barrier protections, and viral load may reduce risks of resistant HIV transmissions in LMIC settings.

7 May 2026 in Journal of Travel Medicine
Verified
Journal Article
Open access
BLBeth Lippman
Beth Lippman
AIAbigail Immanuel
Abigail Immanuel
KDKevin Dieckhaus
Kevin Dieckhaus

23 April 2015
Verified
Book Chapter
Closed access
LCLisa M. Chirch
Lisa M. Chirch
KDKevin Dieckhaus
Kevin Dieckhaus
JGJane Grant-Kels
Jane Grant-Kels

5 February 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
YZYifan Zhang
Yifan Zhang
WCWon Chang
Won Chang
KDKevin Dieckhaus
Kevin Dieckhaus
SJSuyoung Jo
Suyoung Jo
JHJina Han
Jina Han
DKDong-Hyun Kim
Dong-Hyun Kim
Background: Estimating infection risk from SARS-CoV-2 Omicron and post-Omicron sub-variants is challenging due to the high number of unconfirmed infections. We compared breakthrough infection risks among individuals with hybrid, vaccine-only, and infection-only immunity in South Korea, incorporating laboratory-confirmed and serology-inferred infections. Methods: Using nationwide surveillance data (August–December 2022), immunity was classified by vaccination history and spike (S) and nucleocapsid (N) antibody profiles. Outcomes were assessed using two definitions: conservative (laboratory-confirmed cases) and inclusive (serology-inferred infections identified by changes in N-antibody titers). Infection dates for unconfirmed events were imputed via predictive mean matching, enabling Kaplan–Meier analyses. Time-varying Cox models estimated log hazard ratios (log-HRs). Results: Including serology markedly increased four-month cumulative infection risk estimates: hybrid immunity rose from 2% to 20%, infection-only from 4% to 24%, and vaccine-only from 30% to 40%. With these additional infections, the relative advantage of hybrid immunity narrowed. Under the conservative definition, log-HRs declined for vaccine-only vs hybrid (4.10–2.34) and infection-only vs hybrid (1.56–0.31). Under the inclusive definition, the vaccine-only log-HR fell from 3.44 to 0.13, and the infection-only log-HR shifted from 3.31 to −0.56, indicating greater protection for infection-only immunity by month four. Conclusions: Because confirmed cases largely capture symptomatic disease, vaccination appears to provide added protection against severe outcomes, though this benefit wanes within months. The rapid decline of hybrid immunity and the large burden of unconfirmed infections highlight the need for routine serological surveillance to detect silent transmission and timely booster campaigns to mitigate severe disease during Omicron-driven waves.